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Abstract
Background: Fixed-dose combination antimalarial drugs have played an increasingly important
role in the treatment and chemoprophylaxis of falciparum malaria since the worldwide failure of
monotherapy with chloroquine. Atovaquone-proguanil is one such combination drug used both for
prophylaxis in travellers, and for treatment of acute malaria cases in European hospitals and clinics.
Methods: A series of eight atovaquone-proguanil treatment failures and two prophylaxis
breakthroughs from four UK hospitals from 2004–2008 were analysed for evidence of mutations
in the pfcyt-b gene, previously found to be associated with failure of the atovaquone component.
Results: Parasites carrying pfcyt-b mutations were found in five falciparum malaria patients with
recrudescent parasitaemia occurring weeks after apparently successful treatment of a primary
infection with atovaquone-proguanil. Four of these cases carried parasites with the Tyr268Cys
mutation in pfcyt-b, previously reported in two French patients with malaria. In contrast, mutations
in pfcyt-b were not found in three patients treated with atovaquone-proguanil who exhibited
delayed clearance of the primary infection, nor in two returning travellers with malaria who had
used the combination for prophylaxis. Using current and previously published data, mean time to
recrudescence of parasites carrying pfcytb codon 268 mutations was estimated as 28.0 days after
treatment (95% C.I. 23.0 – 33.0 days), whereas treatment failures without codon 268 mutations
received rescue treatment an average of 4.71 days after initial AP treatment (95% C.I. 1.76 – 7.67
days).
Conclusion: Genetically-determined parasite resistance to atovaquone is associated with delayed
recrudescence of resistant parasites three weeks or more after initial clearance of parasitaemia by
atovaquone/proguanil therapy. The 268-Cys allele of pfcyt-b may have been overlooked in previous
studies of atovaquone-proguanil treatment failure as it is not detected by current RFLP methods.
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Background
The hydroxynaphthoquinone compound atovaquone
was developed in the 1990s as an anti-protozoal drug,
with demonstrated activity against cytochrome b in path-
ogen mitochondria. High rates of post-treatment recru-
descence in patients treated with atovaquone alone for
Plasmodium falciparum malaria [1] may be attributable to
de novo mutations in the parasite's pfcyt-b gene that arise
from increased oxidative damage to mitochondrial DNA
generated by the action of atovaquone [2]. This led to
deployment of atovaquone in combination with other
antimalarials, and in particular in a highly synergistic
fixed combination with proguanil as atovaquone/pro-
guanil (AP; Malarone®).
AP is widely used for malaria prophylaxis in travellers,
and for treatment of clinical malaria cases in high income
countries. It is not used as therapy in sub-Saharan Africa
due to its high cost, but there are reports of pfcyt-b muta-
tions in African parasite isolates, mostly following
atovaquone monotherapy or treatment with AP [3-6].
Malaria patients failing AP therapy may carry the resist-
ance-associated pfcyt-b mutations Tyr268Ser or Tyr268Asn
[3,7], although treatment failure is also observed in the
absence of these mutations [8]. Such parasites may have
intermediate in vitro sensitivity to atovaquone compared
to that of parasites carrying codon 268 mutations in pfcyt-
b [5].
DNA sequencing analysis was performed on P. falciparum
cyt-b genes from malaria patients with recurrent parasitae-
mia following treatment with AP in four UK settings, or
following use of AP prophylaxis in a malaria endemic
area. The relevance of these results for malaria treatment
policy in the UK is discussed.
Methods
Parasites were isolated from three categories of patients
with falciparum malaria: those whose clinical and parasi-
tological response to AP was delayed in the first three days
following AP treatment, those with microscopically con-
firmed recrudescent parasitaemia following initially suc-
cessful treatment with AP, and three cases where AP had
been taken as prophylaxis during travel in an area of
malaria endemicity. Genotyping of the pfcyt-b gene was
carried out as part of the surveillance remit of the Malaria
Reference Laboratory (MRL), and performed either at the
Department of Clinical Parasitology, Hospital for Tropical
Diseases (HTD) or at the LSHTM Malaria Reference Labo-
ratory (MRL), using identical PCR and sequencing proto-
cols. The MRL is mandated by the UK Health Protection
Agency to provide molecular surveillance in the form of
genetic typing of P. falciparum for drug resistance-associ-
ated alleles, to assist in development of national policy on
prevention and treatment of imported malaria. The work
described was carried out under this mandate. All patient
identifiers have been removed from this report.
A 939 bp portion of the pfcyt-b gene was amplified using
primers cyt-b1 (5'CTC TAT TAA TTT AGT TAA AGC ACA
3') and cyt-b2 (5' ACA GAA TAA TCT CTA GCA CC 3') by
conventional PCR with standard regents. Reaction condi-
tions were used as follows: samples were heated initially
at 93°C for 10 minutes and then at 93°C for 50 s, 45°C
for 50 s and 70°C for 1 min over 50 cycles. PCR products
were purified by fractionation on a 1% agarose gel and
elution with the MinElute Gel Extraction Kit (Qiagen Ltd,
Crawley UK).
PCR products were sequenced using the ABI Prism Big
Dye Terminator kit, using the amplification primers and a
third primer, cyt-b7 (5'-CAA TTA CTA AAC CAG CTG G-
3'), to prime the sequencing reactions. Electropherogram
data were edited, collated and analysed using Chromas
software (Technelysium, Australia). All DNA sequences
were confirmed by at least two independent sequence
reads.
Results
Patients
The sequence surrounding codon 268 of the pfcyt-b gene
was determined for each suspected atovaquone-resistant
parasite isolate. These were obtained from the following
patients:
Patient 1 was a 29 year old male, admitted in October
2004 with uncomplicated falciparum malaria (parasitae-
mia 1.1%). Although ethnically of African origin, he was
born and resident in the UK. Approximately six weeks
prior, this patient had been treated for falciparum malaria
acquired in Sierra Leone with a full course of AP (four tab-
lets daily for three days). His symptoms resolved at that
time, although parasitological confirmation of cure was
not obtained. The recrudescent infection was treated with
quinine/Fansidar® (sulfadoxine/pyrimethamine). Parasite
DNA was extracted from two sequential peripheral blood
samples taken nine hours apart at the time of his recrudes-
cent infection.
Patient 2 was a 44 year-old male who presented in August
2004 with 1% P. falciparum parasitaemia after travel in
Nigeria, where an unspecified antimalarial injection had
been received some weeks earlier. His previous history of
exposure and thus immune status with respect to malaria
is unknown. Parasitaemia rose under treatment with AP to
4% with continuing symptoms on day 3 of admission.
Treatment was then switched to intravenous quinine.
DNA was extracted from a single pre-treatment sample.
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Patient 3 was a 60-year old female treated with a full
course of AP for falciparum malaria in July 2004 follow-
ing a trip to Nigeria. She was a UK resident who had been
brought up in Nigeria. There were no clinical features of
severe disease, although initial parasitaemia was 2.5%.
Sixty-eight hours following the start of her course of AP
she returned with persisting symptoms and a parasitaemia
of 0.1%. She was commenced on a course of quinine ther-
apy and rapidly improved. A blood film taken the follow-
ing day was parasite negative.
Patient 4, a five-year old boy, presented in October 2004
with a 0.1% P. falciparum parasitaemia following a trip to
Nigeria. Although ethnically African, he had lived all his
life in the UK. He made a prompt and unremarkable clin-
ical recovery following a full course of AP. Symptoms
recurred 23 days later and the child re-presented after a
further two days with a 0.3% parasitaemia. DNA was
extracted from a peripheral blood sample taken at the
time of his recrudescent infection.
Patient 5, a 21-year old male resident in London for seven
years but having spent his childhood in Sierra Leone, pre-
sented with a P. falciparum parasitaemia of 0.8% in Sep-
tember 2006 following a visit to his country of origin. He
reported full adherence to AP prophylaxis (one tablet
daily).
Patient 6 was a 56-year old female who presented to hos-
pital with microscopy-confirmed falciparum malaria
within a few days of returning to her home in London
from Nigeria in August 2006. The patient informed hospi-
tal staff of a known allergy to quinine, suggesting sus-
pected malaria infections had been treated in the past. She
was treated with a full course of AP. Persisting parasitae-
mia at 1% after an additional 4th day of AP treatment pre-
cipitated a change to quinine with antihistamine cover,
which cleared the parasites. A blood sample was sent for
DNA sequencing analysis.
Patient 7 was a 30-year old male born and brought up in
Uganda but was a UK resident at the time of the malaria
episode. He was diagnosed with falciparum malaria in
Switzerland in September 2007 after travel to Uganda,
and reported full adherence to a three day therapeutic
course of AP. Parasite clearance was not confirmed micro-
scopically. He presented again in London 21 days after
treatment with 0.2% P. falciparum parasitaemia and was
treated with a course of quinine. DNA was extracted for
analysis from a blood sample collected at the time of his
recrudescent infection.
Patient 8 was a 36-year old male presenting with uncom-
plicated falciparum malaria, parasitaemia less than 0.1%,
in June 2008 after visiting Uganda and Kenya without tak-
ing malaria prophylaxis. This individual was born and
brought up in Uganda, but had been resident in the UK
for 21 years. He was treated with a full 3-day course of AP
and resolution of symptoms was reported over the follow-
ing two days. His symptoms returned 21 days later and a
repeat blood film confirmed recrudescent P. falciparum
parasitaemia of less than 0.1%. Parasite material was ret-
rospectively retrieved from a Giemsa-stained thin film
from the primary episode and compared with results
obtained from the blood sample collected at the time of
recrudescence.
Patient 9 was a 47-year old male presenting with uncom-
plicated falciparum malaria (parasitaemia < 0.1%) in July
2008 after visiting Sierra Leone. He reported good adher-
ence to AP prophylaxis.
Patient 10 was a 47-year old British female who worked in
a rural school in The Gambia from March 2008 to June
2008, and taking mefloquine prophylaxis for that period.
On 30th June, having discontinued chemoprophylaxis,
she travelled to Senegal and within 3 days developed
fever. She received a presumptive diagnosis of malaria,
and took a 3 day course of AP from a back-up supply she
carried with her, and reported that her symptoms
resolved. This individual returned to the UK on the 8th of
July. She took 1 further dose of mefloquine from her
prophylaxis course on return to the UK. She attended her
GP 4 weeks later with fatigue and headache, and a blood
film was P. falciparum positive with a parasite count of 3%.
The patient was treated successfully with quinine followed
by doxycycline.
Sequencing data for the pfcyt-b locus are presented for
these ten patients in Table 1.
Two different mutations at position 268 of the pfcyt-b gene
were identified among the parasite isolates investigated:
patient 4 carried parasites with the Tyr-268-Ser allele of
pfcyt-b as previously described [3], whereas patient 1 (both
samples A and B) and patients 7, 8 (July recrudescent sam-
ple only) and 10 harboured parasites with the Tyr-268-
Cys allele (Figure 1) [5]. Each of these five patients had a
recrudescent P. falciparum infection at least three weeks
after a primary malaria episode which initially resolved
with AP treatment. No cases harbouring the Tyr-268-Asn
allele of pfcyt-b were identified, and no mutations were
identified at any other codons of the pfcyt-b gene. During
his first (June) episode of malaria, Patient 8 harboured
parasites with the wild-type Tyr at codon 268 of pfcyt-b,
but 26 days later only parasites with Cys encoded at posi-
tion 268 were identified.
Patients 2, 3 and 6 exhibited delayed clearance of P. falci-
parum infections in the first 72 hours following initiation
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of AP treatment, precipitating a change in therapy (to qui-
nine in each case). Each patient carried parasites with
pfcyt-b genes that were wild-type at codon 268. Patients 5
and 9 reported good adherence to AP prophylaxis during
visits to malaria endemic zones. Plasmodium falciparum
parasites isolated from both of these patients were wild
type at codon 268 of the pfcyt-b locus.
These results suggest that genetically determined resist-
ance to atovaquone at codon 268 of pfcyt-b is associated
with recrudescence of parasites at least 20 days after
apparently successful AP therapy. To test this possibility,
data from this series of eight patients for whom AP ther-
apy failed were analysed together with ten such patients
described by Musset et al. [5]. Prophylaxis failures
(patients 5 and 9) were not included in the analysis. Seven
of these 18 patients harboured wild-type parasites at the
time of treatment failure, which occurred at a mean of
4.71 days after initial AP treatment (95% C.I. 1.76 – 7.67
days). In contrast, the 11 patients carrying mutations at
codon 268 of pfcyt-b presented with recrudescent infec-
tions on average 28.4 days after treatment (95% C.I. 23.9
– 32.9 days). Therefore, carriage of mutations in pfcyt-b is
significantly associated with delayed recrudescent infec-
tions in these two studies of malaria patients presenting to
European hospitals.
Table 1: Description of patients and sequencing results.
Patient # Sample # Sample Date Hospital/GP Geography AP Use Days since AP treatment Pfcyt-b aa268
1 A (relapse) October 2004 St Thomas' Sierra Leone Treatment 42 Cys
B (relapse) October 2004 Cys
2 A September 2004 Northwick Pk Nigeria Treatment 2 Tyr
3 A July 2004 St Thomas' Nigeria Treatment 3 Tyr
4 A October 2004 St Thomas' Nigeria Treatment 25 Ser
5 A Sept 2006 St Thomas' Sierra Leone Prophylaxis N/A Tyr
6 A Aug 2006 Homerton/HTD Nigeria Treatment 4 Tyr
7 A Sept 2007 St Thomas' Uganda Treatment 21 Cys
8 A (pre-treat) June 2008 St Thomas' Uganda/Kenya Treatment 26 Tyr
B (relapse) July 2008 Cys
9 A July 2008 St Thomas' Sierra Leone Prophylaxis N/A Tyr
10 A August 08 Bristol Gambia/Senegal Treatment 32 Cys
DNA sequence encoding amino acids 259 – 279 of pfcyt-b in 10 P. falciparum isolates from UK malaria patientsFigure 1
DNA sequence encoding amino acids 259 – 279 of pfcyt-b in 10 P. falciparum isolates from UK malaria patients. 
Patients 1, 7, 8 and 10 represent four instances of the recently confirmed 268-Cys genotype. Patients 2, 3, 5, 6 and 9 carry the 
wild-type genotype (268-Tyr), and patient 4 the previously reported atovaquone-resistant genotype (268-Ser).
Patients 1,7,8,10 gtacctgaatggtactttctaccattttgtgcaatgttaaaaactgttccaagtaaacca
Mutant 268Cys V P E W Y F L P F C A M L K T V P S K P
Patient 4 gtacctgaatggtactttctaccattttctgcaatgttaaaaactgttccaagtaaacca
Mutant 268Ser V P E W Y F L P F S A M L K T V P S K P
Patients 2,3,5,6,9 gtacctgaatggtactttctaccattttatgcaatgttaaaaactgttccaagtaaacca
Wild-type 268Tyr V P E W Y F L P F Y A M L K T V P S K P
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Discussion
Atovaquone-proguanil (AP) has been widely adopted in
the UK as a chemoprophylactic agent for travellers likely
to be exposed to P. falciparum infections. AP is also widely
employed as first-line treatment for cases of uncompli-
cated falciparum malaria in a number of London hospi-
tals. Reports of AP treatment failure in the UK and Europe
describe substitution of Tyr with Asn, Ser or Cys at codon
268 of the pfcyt-b gene in recrudescent parasites, typically
three to five weeks after the initial malaria infection has
been cleared by AP treatment [3]. Five further cases of P.
falciparum recrudescence three to six weeks after initially
successful AP treatment for uncomplicated malaria in
travellers are described here. Parasites from one of these
patients carried the Tyr-268-Ser mutant allele of pfcyt-b
and the remaining four carried the Tyr-268-Cys allele. The
268-Cys allele has recently been reported in two French
patients with P. falciparum malaria [5], but was first
described in cyt-b genes of drug-selected Plasmodium yoelii
isolated from atovaquone-treated mice [2]. This is the sec-
ond report of this allele in human malaria infections.
In one case, patient 8, it was possible to compare the pfcyt-
b sequence of recrudescent parasites with that of parasites
present 26 days earlier. As previously observed [9], the
appearance of parasites with the mutant pfcyt-b locus only
among recrudescent parasites suggests that this mutation
arose de novo in this individual due to AP selection. How-
ever, pfcyt-b mutations have been found among African
parasite isolates without a history of atovaquone exposure
[6], and it remains a possibility that such parasites occur
at low prevalence in malaria endemic areas, and are occa-
sionally selected by AP treatment of travellers in particu-
lar. Examination of mitochondrial sequences for evidence
of selective sweeps around the mutant pfcyt-b loci, suggest-
ing spread of a restricted number of mutant clones, would
be instructive [10].
In contrast, three patients exhibiting persistent parasitae-
mia after 60 – 90 hours of AP treatment harboured para-
sites with wild-type pfcyt-b loci. The poor response to
treatment in these patients infected by apparently
atovaquone-sensitive parasites is consistent with the find-
ings of Musset et al [5], who demonstrated low plasma
levels of atovaquone, proguanil and cycloguanil (an active
metabolite of proguanil) in four patients with slow-clear-
ing infections immediately following AP treatment. Para-
sites isolated from these patients exhibited in vitro
sensitivity to atovaquone, and did not carry mutations at
codon 268 of the pfcyt-b locus. Malabsorption of
atovaquone is thus one possible cause of reduced drug
plasma levels and poor AP treatment response in the first
few days following initiation of therapy. Drug levels were
not determined for any of the patients described here, but
such measurements would have strengthened the study.
Two travellers presenting in the UK with P. falciparum
infection despite AP prophylaxis-use harboured parasites
with a wild-type pfcyt-b locus. It is unclear whether the fail-
ure of prophylaxis in these two cases was due to poor
absorption of atovaquone, sub-optimal adherence to the
prophylaxis regimen or other unknown parasitological or
host factors. Measurement of plasma levels of atovaquone
in these patients may have helped to resolve these possi-
bilities. A third UK traveller who used mefloquine proph-
ylaxis for only part of her time at risk of malaria infection,
patient 10, reported self-treatment with AP for fever while
in Senegal. Thus the parasitaemia diagnosed in the UK is
almost certainly a recrudescence of the first infection
treated with AP some weeks earlier and so this case is con-
sistent with the general observation that pfcyt-b mutations
are associated with late recrudescent P. falciparum parasi-
taemia. The partial use of mefloquine prophylaxis in this
particular case history, including an additional dose after
return to the UK, one month before the appearance of
recrudescent parasites, raises the possibility these parasites
were also mefloquine resistant.
The conclusion that mutations at codon 268 of pfcyt-b
are associated with delayed recrudescence of parasites
after AP therapy is only partly in agreement with the
findings of a large multicentre study, in which several
cases of AP treatment failure were not associated with
pfcyt-b mutations [4]. At least one of these cases repre-
sented a lack of response immediately after treatment,
rather than a recrudescence. Four patients assessed by
these authors experienced parasite recrudescence three
to five weeks following AP treatment, but only one har-
boured parasites with the Tyr-268-Ser allele of pfcyt-b.
However, Wichmann and colleagues used the RFLP
method of Schwöebel et al [11] to identify pfcyt-b muta-
tions. Examination of the respective recognition site
sequences verified that, firstly, the restriction enzymes
employed in this method, NsiI and AlwNI, will not
digest the Tyr-268-Cys allele found in three patients
reported here and secondly, that this allele would be
erroneously identified as a wild-type Tyr due to diges-
tion only by the enzyme SspI. Therefore, it is possible
that the remaining three individuals described by Wich-
man et al [4] as having recrudescent parasitaemia some
weeks after AP treatment were harbouring the Tyr-268-
Cys allele, which was not detected by the RFLP method.
Although these authors state that mutations at other
positions in the pfcyt-b gene were ruled out by sequenc-
ing a 716 bp PCR fragment, no data are shown to indi-
cate whether or not the Tyr-268-Cys allele was or was
not present. The results of the present study, and those
of Musset et al [5], emphasize the importance of DNA
sequencing approaches in identifying emerging, as
opposed to established, drug resistance in malaria par-
asites.
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The findings reported here can inform both treatment pol-
icy and advice given to prospective travellers to malaria
endemic areas. Current data suggest that AP affords highly
effective prophylaxis for endemic region travel, and is an
efficacious treatment for uncomplicated cases of imported
malaria. However studies with adequate follow-up of
both treated cases and prophylaxis users are needed to ver-
ify these observations. Denominators for our study are
difficult to estimate and, in the absence of active follow-
up, some treatment failures may have presented for re-
treatment elsewhere or not at all. Estimates from one of
the hospitals participating in this study (St Thomas') are
that AP alone was used to treat approximately 280
patients with confirmed P. falciparum malaria from Jan
2004 to December 2007. During this period only three
apparent treatment failures have been confirmed as carry-
ing parasites with pfcyt-b mutations, suggesting a resist-
ance rate of approximately 1%. It is also worth noting that
two of these cases occurred in non-immune patients. Bear-
ing in mind that approximately 90% of falciparum
malaria cases at St. Thomas' hospital affect semi-immune
individuals who were born and brought up in endemic
areas, this suggests that the acquired immunity to malaria
enjoyed by many malaria patients may reduce the risk of
occurrence of recrudescent infection associated with pfcyt-
b mutations, as previously observed in studies of
atovaquone monotherapy [1].
The results presented here also provide some support for
the suggestion of Musset et al [5] that treatment failure
after AP treatment may be caused by poor atovaquone
bioavailability in some patients, and that slow clearance
of parasites after AP treatment may be misinterpreted as
treatment failure [4]. Preliminary results using quantita-
tive SYBRgreen PCR in real-time, suggest that quinine
treatment clears parasites approximately 40% faster than
AP, and this delay in effect may also lead to some over-
reporting of AP resistance in vivo.
Conclusion
A series of P. falciparum isolates from malaria patients in
the UK suspected of AP treatment (or prophylaxis) failure
were tested for mutations in the pfcyt-b locus by direct
DNA sequencing of PCR amplified products. Five patients
with late, recrudescent treatment failure harboured muta-
tions at position 268, and four of these were the recently
described Tyr-268-Cys allele. This allele would not have
been detected by restriction fragment analyses used in
other studies. Three patients with apparent early treat-
ment failure did not carry mutations, and may have failed
to clear parasites due to low bioavailability of
atovaquone. For purposes of drug resistance surveillance,
DNA sequencing of the pfcyt-b locus is recommended in
cases of late recrudescence of P. falciparum malaria, but
may not be indicated where initial treatment response is
delayed.
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